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The objectives of this study were to explore whether
ovarian vascular endothelial growth factor (VEGF) expres-
sion in mice can be regulated by IL-6 (interleukin-6), angio-
tensin II, FSH, and hCG; and to test whether the mouse
ovarian VEGF expression can result in angiogenesis. The ICR
mice were sacrificed, and their ovaries were recovered. Re-
covered ovaries were treated with IL-6, angiotensin II, FSH,
and hCG separately and incubated for 24 hours in -MEM. α
Expression of mRNA and protein of VEGF were assessed by
RT-PCR and immunohistochemistry. The resulting angioge-
nesis was evaluated through immunohistochemical analysis
for CD34. Treatment of mice ovaries with IL-6, FSH, and
hCG resulted in a significant increase of VEGF mRNA, and
IL-6 was the most potent inducer of VEGF. IL-6 and FSH
resulted in increased neovascularization in the follicular phase
of mouse ovaries. In contrast, angiotensin II could not
increase VEGF expression or neovascularization. We docu-
mented an in vitro increase in VEGF expression by IL-6,
FSH, and hCG; and reaffirmed that the proliferative response
of murine ovarian endothelial cells paralleled an increase of
VEGF expression.
Key Words: Angiogenesis inducing agents, follicle stimulating
hormone, interleukin-6, ovary, vascular endothelial growth
factors
INTRODUCTION
The female reproductive system undergoes a
number of programmed angiogenic processes,
coupled with cyclic changes in the ovarian and
endometrial structures. Furthermore, it is well
known that a number of female reproduction sys-
tem disorders are associated with alteration of
physiologic angiogenesis or with pathologic an-
giogenesis. Dysfunction in ovarian angiogenesis
may contribute to a variety of disorders including
anovulation, infertility, pregnancy loss, ovarian
hyperstimulation syndrome, and ovarian neo-
plasms.
1
Angiogenesis of the ovary is initiated early dur-
ing follicular development and continues through-
out follicular growth.
2 The preovulatory follicle
acquires a complex vascular network and the
granulosa cells receive a rich vascular supply from
the thecal capillaries penetrating the basement
membrane. This dynamic change in angiogenesis
differs from one follicle to another, and the selec-
tion of the dominant follicle may depend on the
differential formation of this rich vascular supply.
1,3
Vascular endothelial growth factor (VEGF) is a
specific mitogen for vascular endothelial cells and
has a central role in ovarian angiogenesis. It has
been suggested that several factors are involved in
the dynamic pattern of VEGF expression during
follicular growth. Chistenson et al demonstrated a
role for a midcycle surge of gonadotropin in pri-
mates to promote VEGF production by granulosa
cells in the periovulatory follicle of Rhesus mon-
keys.
4 The treatment of various cell lines with IL-6
resulted in a significant induction of VEGF
mRNA,
5 and angiotensin II has been shown to
stimulate the expression of angiogenic factors in
bovine luteal cells.
6 These results suggest the pre-
sence of regulators of VEGF expression in the
ovary. Most of these studies were performed
during late follicular or luteal phase. However,
little is known about the VEGF regulation during
follicular phase.
The aim of this study is to address this issue,
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first by identifying several factors such as IL-6,
angiotensin II, hCG, and FSH which regulate the
VEGF expression during the follicular phase; and
second, by identifying the changes of VEGF ex-
pression, if any, resulting from these factors,
which may contribute to neovascularization.
MATERIALS AND METHODS
Treatment of mouse ovaries
Thirty 6-week-old ICR mice were killed and
their ovaries were removed. Ten mice were used
for RT-PCR, another 10 mice for immunohisto-
chemistry for VEGF, and the remaining 10 mice
for immunohistochemistry for CD34. Out of the 2
ovaries of each mouse, the larger ovary was re-
moved and sliced into 5 pieces using an operative
microscope. The ovaries were incubated for 24
hours in α-MEM medium containing 1 M angio μ -
tensin II (Human angiotensin II acetate, Sigma,
Germany), 50 ng/mL IL-6 (Recombinant mouse
IL-6, Sigma, Germany), 7.5 mIU/mL FSH (Gonal-
F, Serono, Switzerland), or 500 mIU/mL hCG
(Profasi, Serono, Switzerland) for each group.
RT-PCR
Ovarian tissue was homogenized in 1 mL TRIzol
reagent (Gibco BRL, Life Sciences, Carlsbad, CA,
USA). Total RNA was separated from DNA and
proteins by adding chloroform and precipitated
with the use of isopropanol. The precipitate was
washed twice in 75% ethanol, air dried, and
rediluted in DEPC-treated distilled water. The
amount and the purity of the isolated RNA were
quantified by spectrophotometry.
One g of total RNA was used to synthesize μ
cDNA using a 1
st strand cDNA synthesis kit
(Roche, Diagnostics Corp. Indianapolis, IN, USA).
Mastermix per sample was prepared as follows: 2
L μ of 10 × reaction buffer, 2 L μ of 10
-3 M dNTP
mixture, 2 L μ of 2.5×10
-3 M oligo-p(dt)15, 4 L μ of
5 ×10
-3 M MgCl2, 0.8 L μ of 50 U RNase inhibitor,
and 1 L μ of 20 U AMV-reverse transcriptase. The
mixture was incubated at room temperature for 10
minutes, 42 for 1 hour, then at 95 for 5
minutes using a PCR thermal cycler. To amplify
cDNA, 2 L μ total cDNA from each RT tube were
mixed with Mastermix containing 50×10
-3 M KCl,
10×10
-3 M Tris-HCl (pH 9.0), 0.1% Triton X-100,
2×10
-3 M MgCl2, 10×10
-3 M dNTP mixture, 1.25 IU
Taq polymerase, and 50 pmol of each primer for
VEGF or -actin. β
The VEGF primers were designed to amplify a
region common to all VEGF isoforms. The sense
VEGF primer (5'-GAA GTC CCA TGA AGT GAT
CAA G-3') and primer 3' of each isoforms were
used (Table 1). The PCR products for 5 isoforms,
VEGF 120, VEGF 144, VEGF 164, VEGF 188, and
VEGF 205 would be 331, 404, 333, 407, and 425bp,
respectively.
PCR reactions were carried out with the follow-
ing program, first heated to 94 for 5 minutes,
then 28 cycles of 94 for 30 seconds, 62 for 30
seconds, and 72 for 30 seconds, with a final elon-
gation step at 72 for 10 minutes. The electro-
phoresis of the PCR product was carried out in
2% agarose gel stained with 0.5% ethidium bro-
mide. After completion of electrophoresis, the
bands were analyzed on an image analyzer.
Immunohistochemistry
Ovarian tissues were fixed in 10% formalin in
PBS and then embedded in paraffin. Paraffin-em-
bedded ovaries were sectioned in 4 m thick μ ness.
Table 1. 3` Primer Sequences of 5 VEGF Isoforms
VEGF isoform Sequence
VEGF 120 5' CGG CTT GTC ACA TTT TTC TGG C-3'
VEGF 144 5' TCG GCT TGT CAC ATA CGC TC-3'
VEGF 164 5' CAA GGC TCA CAG TGA TTT TCT GGC-3'
VEGF 188 5' AAC AAG GCT CAC AGT GAA CGC T-3'
VEGF 205 5' TCC AGG GCA TTA GAC AGC A-3'
VEGF, Vascular endothelial growth factors.The Regulators of VEGF Expression in Mouse Ovaries
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The tissue sections were deparaffinized in xylene
and dehydrated in a graded series of ethanol. An
immunohistochemistry for VEGF was performed
with streptoavidin-biotin-peroxidase complex
method using goat antimouse VEGF polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The endogeneous peroxidase was
quenched with 3% hydrogen peroxide at room
temperature for 5 minutes, then the tissue sections
were rinsed three times for 5 minutes each time
in TBS. The sections were incubated with normal
serum, then incubated with goat antimouse VEGF
polyclonal antibody at a dilution of 1:200 in PBS/
BSA overnight at 4 . After three washes with TBS
for 15 minutes each, the sections were incubated
with biotinylated secondary antibody for 60 minutes
at room temperature and washed three times. The
samples were incubated with streptavidin-pero-
xidase conjugate in PBS for 30 min at room tem-
perature, washed three times, and incubated with
3.3'Diaminibenzidine chromogen in Tris buffer
containing H2O2 for 5 minutes. Immunohistoche-
mistry for CD34 was performed by the avidin-bio-
tin-peroxidase complex method using mouse anti-
CD34 monoclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Counterstaining
was performed with Mayer's hematoxylin. The
results were assessed by one pathologist as -, +,
++, and +++. In CD34 immunostaining, only stro-
mal staining was regarded as neovascularization.
Statistical analysis
Data obtained for VEGF mRNA expression are
presented as means and standard error. RT-PCR
data were analyzed by a one-way analysis of
variance (ANOVA) with a significance level set at
p < 0.05. Data of immunohistochemistry were
evaluated by Friedman's two-way ANOVA and p
values < 0.05 were considered significant.
RESULTS
The expression of VEGF mRNA
The predominant isoforms of VEGF were VEGF
120 and VEGF 164. VEGF 144 was expressed in
very low levels (Fig. 1, 2). As VEGF 188 was not
expressed in vivo and VEGF 144 was expressed in
very low levels, we excluded these isoforms from
the data analysis.
The treatment with IL-6 increased the VEGF
mRNA expression. The ratio between VEGF 120
and actin increased from 0.75 to 1.17 (p = 0.012),
and the ratio between VEGF 164 and actin in-
creased from 0.65 to 0.92 (p = 0.036, Fig. 1).
The exposure of mouse ovary to FSH resulted
Fig. 2. The semiquantitative RT-PCR analysis of the gene
expressions of the specific VEGF isoforms were nor-
malized with the expression of the housekeeping gene, β-
actin. M: Molecular weight marker, Cont: control, IL-6:
interleukin-6, FSH: Follicle stimulating hormone, hCG:
Human chorionic gonadotrophin, Ang II: Angiotnesin II.
Fig. 1. The values on the Y-axis represent mean values of
the ratio between VEGF and actin. *p =0.012
§p =0.036 p =
0.009 p = 0.015 p = 0.023
¶p = 0.054.So-Young Shin, et al.
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in induced VEGF 120 mRNA (p = 0.009) and VEGF
164 (p = 0.015). Similarly, the hCG treated mouse
ovary resulted in increased VEGF 120 mRNA (p =
0.023) and VEGF 164 (p = 0.054, Fig. 1).
Although there was an increasing trend in the
expression of VEGF mRNA with treatment of
angiotensin II, it did not reach statistical signifi-
cance.
Immunohistochemistry of VEGF and CD34
In the IL-6 and FSH treated mouse ovaries,
VEGF immunostaining seemed to have increased
even though it did not reach statistical signifi-
cance (p = 0.0845, Table 2, Fig. 3). The result of
CD34 immunostaining revealed an increase of
small sprouting capillaries when IL-6 was used. A
similar trend was observed with VEGF staining
(p = 0.0458, Table 3, Fig. 4).
DISCUSSION
In most adult tissues, angiogenesis occurs only
rarely during tissue repair. Pathological angioge-
nesis is associated with various disorders, in-
cluding tumor growth,
7 diabetic retinopathy,
8
rheumatoid arthritis,
9 and atherosclerotic lesions.
10
The female reproductive tract is unique because
this is the only site in the uninjured adult body
where angiogenesis occurs in a repetitive cyclic
fashion, modulated by various factors.
11 Further-
more, these dramatic changes in the ovarian vas-
culature are associated with follicle growth,
atresia, and corpus luteal development and re-
gression. This ovarian angiogenesis is a complex
process in which a delicate balance between pro-
moters and inhibitors is maintained. Disturbance
of this balance may result in a disrupted physio-
logic state or various pathologic conditions such
Fig. 3. (A) Immunohistochemical stai-
ning showing VEGF expression of a
mouse ovary. (B) VEGF expression in
a mouse ovary treated with IL-6. (C)
VEGF expression in a mouse ovary
treated with FSH. (D) VEGF expres-
sion in a mouse ovary treated with
hCG. (E) VEGF expression in a mouse
ovary treated with Angiotensin II.
Table 2. VEGF Staining Intensity of Follicles
Staining intensity Control (n = 10) IL-6 (n = 10) FSH (n = 10) hCG (n = 10) Ang II (n = 10)
- 4 1 1 2 5
+ 4 3 4 4 3
++ 2 4 5 3 2
+++ 0 2 0 1 0
VEGF, Vascular endothelial growth factors; IL-6, Interleukin-6; FSH, Follicle stimulating hormone; hCG, Human chorionic gonadotro-
phin; Ang II, Angiotnesin II.
*p = 0.0845, Analyzed by Friedman’s two- way ANOVA.
A B C
D EThe Regulators of VEGF Expression in Mouse Ovaries
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as polycystic ovarian syndrome, ovarian hypersti-
mulation syndrome, and benign and malignant
neoplasms.
11
A critical regulator of ovarian angiogenesis is
VEGF. VEGF is a mitogen for vascular endothe-
lium and exists in five isoforms resulting from
alternative splicing of the same gene.
1 VEGF ex-
pression varies during the ovarian cycle. The
VEGF mRNA and protein are initially absent from
the granulosa cell of the primordial follicle and
the preantral follicles but become evident in the
theca cells of antral follicles and in the granulose
cells nearest the oocyte in preovulatory follicles.
During the periovulatory interval, VEGF levels in
the follicular fluid increase markedly.
3,11 After
ovulation, VEGF mRNA and protein expression
are observed in the granulosa and theca-derived
luteal cells.
12
The dramatic changes in ovarian angiogenesis,
especially VEGF expressions, are associated with
follicle growth and atresia.
12 However, elevated
follicular fluid levels of VEGF are observed in
poor responders, which is related to reduced oxy-
gen delivery, resulting from an increased resis-
tance at the level of the perifollicular arteries.
13
VEGF is expressed not only in follicles but also
in the stroma of the ovary, which provide nutri-
tional support for primordial and primary follicles
that survive in large proportion during cryo-
preservation and transplantation. Thus, it is likely
that the regulation of VEGF in the ovarian folli-
cular phase produces benefits in ovarian stimula-
tion of poor responders and also in ovarian tissue
grafted protocols.
Several mechanisms are involved in the regula-
tion of VEGF gene expression. VEGF mRNA is
highly expressed by the induction of hypoxia via
hypoxia-inducing factor-1 (HIF-1). Many cytokines
and growth factors, such as transforming growth
factor (TGF)-α, basic fibroblast growth factor
Table 3. CD34 Staining Intensity of Endothelial Cells
Staining intensity Control (n = 10) IL-6 (n = 10) FSH (n = 10) hCG (n = 10) Ang II (n = 10)
6 3 3 2 5
+ 3 0 2 7 4
++ 1 3 5 0 1
+++ 0 4 0 1 0
IL-6, Interleukin-6; FSH, Follicle stimulating hormone; hCG, Human chorionic gonadotrophin; Ang II, Angiotensin II.
*p = 0.0458, Analyzed by Friedman’s two- way ANOVA.
Fig. 4. (A) Immunohistochemical stai-
ning showing CD 34 of a mouse ovary.
(B) CD34 expression in a mouse ovary
treated with IL-6. (C) CD34 expression
in a mouse ovary treated with FSH.
(D) CD34 expression in a mouse ovary
treated with hCG. (E) CD34 expression
in a mouse ovary treated with
Angiotensin II.
A B C
D ESo-Young Shin, et al.
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(bFGF), intelerukin-6, and angiotensin II, could
also induce VEGF mRNA expression and protein
secretion in various tissues.
7 Besides, lysophos-
pholipidic acid (LPA) and cell differentiation also
play important roles in the regulation of VEGF
expression.
1 There is a suggestion that different
regulatory pathways are involved in VEGF regu-
lation. However, what exactly causes the regula-
tion of this critical angiogenic factor in the ovary
remains to be established. Moreover, the mole-
cular mechanisms that regulate the VEGF expres-
sion during the early follicular phase are not
elucidated.
To identify the respective angiogenic factors in
the follicular phase of the ovary, the present study
was focused on VEGF, a major angiogenic factor
that is responsible for cyclic angiogenesis of the
female reproductive tract, and its regulators in the
follicular phase.
We evaluated whether IL-6 could induce VEGF
expression. IL-6 is a cytokine that acts on various
cell types. Motro et al. demonstrated that IL-6
mRNA is transiently expressed during angio-
genesis that accompanies folliculogenesis, sug-
gesting its angiogenic role.
14 When IL-6 was ad-
ded to the culture media, we found that the VEGF
mRNA expression increased significantly. Our
data suggest that IL-6 might be considered as an
indirect inducer of angiogenesis that exerts its
activity through the induction of VEGF. More-
over, it is noteworthy that, among the other fac-
tors included in our study, IL-6 was the most
potent inducer of VEGF expression.
Several studies suggest that FSH and LH/hCG
modulate the expression of VEGF. Christenson
demonstrated that the midcycle surge of FSH and
LH/hCG in primates promotes VEGF production
by granulosa cells in the periovulatory follicle.
4 As
expected from previous studies, our study sup-
ports the evidence of gonadotropin's role in an-
giogenesis.
4,15 VEGF production stimulated by
gonadotropin leads to more blood flow and more
input of gonadotropin, in particular, to the domi-
nant follicle of the natural cycle.
16 Although a
possible role of protein kinase C is suggested,
cAMP-dependent protein kinase A plays a key
role in the gonadotropin-dependent increase in
VEGF production. The latter is supported by one
particular study, which demonstrated the stimula-
tory effect of both gonadotropin and 8-Br-cAMP
on VEGF production by Leydig cells.
17
Therefore, our observations are indicative of
important features in determining that gonadotro-
pin is a potent stimulator of angiogenic growth
factor, which might be of benefit in the challeng-
ing field of ovarian grafting and in vitro matura-
tion. As shown in our study, gonadotropins could
up-regulate VEGF, and exogeneous gonadotropin
could increase the number of surviving follicles in
ovarian tissue grafts.
18 This result was supported
by the observation that use of gonadotropins may
be beneficial in vitro maturation of oocytes.
19
Although several studies indicated the proan-
giogenic role of angiotensin II, which exerts effects
through two distinct subpopulations of angio-
tensin II receptors, AT1 and AT2,
20,21 our study
could not observe any correlation between the
expression of angiotensin II and VEGF. This is in
contrast to an earlier finding showing that angio-
tensin II might regulate VEGF expression.
Tamarat et al demonstrated that angiotensin II
induced an increase of VEGF in mice.
21 Hayashi
et al suggested that angiotensin II might regulate
angiogenesis in the developing bovine corpus
luteum.
6 This discrepancy may be explained by
several studies indicating the variation in angio-
tensin II receptor distribution and concentration
among species. In rat ovaries, the AT1 receptor
was primarily found in the stroma, whereas AT2
was expressed on the granulosa cells of atretic
follicles.
22 In contrast, rabbit granulose cells ex-
press AT2 receptors in the preovulatory follicle.
23
Further studies are necessary to gain insights as
to how angiotensin II induces neovascularization
in different species, in particular in human
ovaries.
In addition, we evaluated whether the increase
in VEGF mRNA by several factors resulted in
VEGF protein production through immunohisto-
chemistry. Although we could not obtain a
statistical significance, there was an increasing
tendency in VEGF staining (Fig. 3). However, we
did observe more CD34 positive cells in IL-6 and
FSH, in which VEGF mRNA levels were increased
(Fig. 4). The discrepancy between mRNA expres-
sion and immunohistochemisty of VEGF might
have resulted because of the small number of
mouse ovaries. Another possible explanation isThe Regulators of VEGF Expression in Mouse Ovaries
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that some modification in regulation at the post-
transcriptional level might exist, resulting in dif-
ferences between mRNA and protein expression.
These data, however, strongly argue in favor of
the important influence of IL-6 and FSH in me-
diating the induction of the VEGF protein and
finally ovarian angiogenesis during the follicular
phase of the ovary.
CD34 is known to be a specific marker for endo-
thelial cells and is used to study ovarian blood
vessels.
24 The endothelial cell layer of small ves-
sels in the superficial ovarian stroma tended to be
positive for CD34 in IL-6 and FSH treated ovaries,
in contrast to the control and angiotensin II-
treated ovaries for which that was the case in only
a few blood vessels.
Because perifollicular angiogenesis supplies
gonadotropins and many growth factors to the
granulosa cells of follicles, angiogenesis of stroma
is associated with the promotion of follicular
development. While Shimizu et al. demonstrated
that VEGF-treated ovaries of miniature gilts pro-
moted perifollicular vascularization,
25 our data
might support the concept that VEGF also pro-
mote perifollicular angiogenesis that is essential
for follicles in the early stage.
In summary, we demonstrated that IL-6, FSH,
and hCG are angiogenic factors that act indirectly
by inducing VEGF expression in mouse ovaries.
This evidence, supplemented by immunohisto-
chemical data indicative of VEGF activity, pro-
vides the possibility that ovarian angiogenesis
might be regulated through the induction of
VEGF expression by IL-6, FSH, and probably
hCG.
This issue should be a subject for further clinical
investigation because induced neovascularization
by the regulation of VEGF would be a challenging
therapeutic approach in female reproductive dis-
eases. Furthermore, in the future, this VEGF regu-
lation may assist in the application of antian-
giogenic medications in the therapy of conditions
including polycystic ovary syndrome, ovarian
hyperstimulation, and ovarian carcinomas.
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